FDA Approved: GEMFIBROZIL — Supplemental Application (Cadila Pharmaceuticals Limited)

View source ↗

Summary

FDA approved a supplemental application for gemfibrozil filed by Cadila Pharmaceuticals Limited, changing the labeling of this generic lipid-lowering medicine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipidemia
• Hypertriglyceridemia
• Mixed Dyslipidemia

Drugs mentioned

• Gemfibrozil (Gemfibrozil)

Snippet

SUPPL AP for GEMFIBROZIL (GEMFIBROZIL)